What do systematic reviews say?

Interferon‐α alone vs interferon‐α plus bevacizumab

The review found no eligible studies for this question.

• Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Peginterferon alpha‐2a vs peginterferon alpha‐2b

• Peginterferon alpha‐2a versus peginterferon alpha‐2b for chronic hepatitis C 2014 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 434 participants
  Very low

Interferon vs no intervention

It is very uncertain whether interferon changes health‐related quality of life (1 week) compared with no intervention (very low certainty).

• Pharmacological interventions for acute hepatitis B infection 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 100 participants
  Very low

Interferon‐α plus bevacizumab vs standard targeted therapies

The review found no eligible studies for this question.

• Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Injectional interferon alpha‐2B vs Normal saline

The review found no eligible studies for this question.

• Non‐surgical therapies for Peyronie's disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Interferon‐α combined with targeted therapies vs standard targeted therapies

The review found no eligible studies for this question.

• Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Neoadjuvant immunotherapy (high dose interferon) plus chemotherapy vs neoadjuvant chemotherapy

The review found no eligible studies for this question.

• Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Sunitinib vs IFN‐α (targeted agent versus classic immunotherapy)

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 544 participants
  Moderate

Intravesically administered BCG alternating with IFN‐α vs intravesically administered BCG alone

The review found no eligible studies for this question.

• Intravesical Bacillus Calmette‐Guérin with interferon‐alpha versus intravesical Bacillus Calmette‐Guérin for treating… 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intravesically administered BCG combined with IFN‐α vs intravesically administered BCG alone

The review found no eligible studies for this question.

• Intravesical Bacillus Calmette‐Guérin with interferon‐alpha versus intravesical Bacillus Calmette‐Guérin for treating… 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found